
    
      This study is a Phase 2A, randomized, double-blinded, placebo-controlled, two-period
      crossover study to evaluate the effect of two doses of SXC-2023 on measures of impulsivity
      and inhibitory control, urge for cigarettes, and mood in non-treatment seeking smokers who
      are abstaining from smoking. The study consists of a screening period of up to 30 days, a 5
      day randomized double-blind treatment period, a 9 day washout period, followed by a second 5
      day randomized double-blind treatment period, with a safety follow-up period 7 days after the
      last dose of study medication.
    
  